ProCE Banner Activity


Navigating a New Era of Targeted Treatments for Postpartum Depression


On-demand webcast of expert faculty presentation and case discussion on novel treatment strategies for managing patients with postpartum depression, from CCO’s Psychiatry Summit 2024.

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: May 31, 2024

Expiration: May 30, 2025



Anita H. Clayton

Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Sage Therapeutics, Inc. and Biogen.


Sage Therapeutics, Inc.

Target Audience

This program is intended for HCPs who treat patients with PPD, including psychiatrists, nurse practitioners, nurses, pharmacists, and physician associates.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners to optimize treatment for patients with depression.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Formulate strategies for achieving an early diagnosis of PPD

  • Summarize the latest hypotheses for the pathophysiology of PPD

  • Interpret the latest efficacy and safety evidence for new and emerging treatments for PPD


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Anita H. Clayton, MD, DLFAPA, IF: grants: Daré Bioscience, Janssen, Neumora, Otsuka, Relmada; consultant/advisor: AbbVie, Biogen, Brii Biosciences, Fabre-Kramer, Initiator Pharma, Janssen Research & Development, Mycomedia Life Sciences, PureTech Health, Reunion Neuroscience, S1 Biopharma, Sage Therapeutics, Sertsei, Vella Bioscience; stock/stock options: Mediflix, S1 Biopharma. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Michael Asbach, DMSc, PA-C, as noted below.​

 Michael Asbach, DMSc, PA-C: consultant/advisor/speaker: AbbVie, Avanir, Intra-Cellular, Janssen, Neurocrine, Otsuka, Sage/Biogen.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 31, 2024, through May 30, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hours, including 1 hour of pharmacotherapy credit. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-125-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit to create your account.